Report me for selling fake medicine? Why are you crying when your illness relapses?

After hearing this,

Anna's expression also became solemn, and she started reading the report immediately.

At this time, everyone knew that Pfizer would definitely make a big move.

The main reason is that the stock price has fallen too sharply, and the revenue of various businesses has also been declining. We must find a way to restore market confidence.

But if Pfizer wants to restore market confidence, it will inevitably affect the performance of other pharmaceutical companies. The market is so big that if someone takes a bigger bite, someone else will take a smaller bite.

Therefore, she also needs to pay great attention to Pfizer's series of actions.

“Is Pfizer so lucky?”

“This kind of project can find returns, which should be very ideal.”

"I just don't know how much it will cost Pfizer to get it, but as long as it can be done, it will certainly restore market confidence."

After reading the research report of the project,

Anna couldn't help but feel a little envious. This was indeed a very high-quality project.

If Pfizer successfully wins this project, it may be able to restore market confidence with this project, and the stock price will probably rise again soon, or at least will not fall again.

The most important thing is that the success rate of this anti-cancer drug project has been very high to date. If it is basically completed, the possibility of failure will be very small.

As for how big the market for this anti-cancer drug will be, it depends on how effective the drug itself is and how Pfizer operates it.

……

……

“Keep your eye on this project.”

"Also, let our market research department follow up on this project."

"If we can't reach an agreement with Pfizer, and the price is within our acceptable range, we can try to get it."

After putting down the research report, Anna quickly made a decision.

Of course, she hoped to acquire Chen Xuan's drug patent, but this opportunity obviously no longer existed, so she naturally had to shift her target to other drug patents.

The anti-cancer drug that Pfizer has discovered now does have great potential and is worth acquiring.

However, there are also unspoken rules among pharmaceutical giants. Generally, they will not compete for the same project casually. The emphasis is on first come first served.

After all, if multiple giants compete for a project, a project that was originally worth $100 billion may eventually be competed for $10 billion.

In order to avoid this kind of malicious competition, we have to adopt the implicit rule of first come first served.

Of course, if you really come across a high-quality project that is guaranteed to make money, then there will be no such thing as unspoken rules.

As long as core interests are involved, no pharmaceutical company will care about first come first served. It is not a big deal to just fall out with each other. Just get the benefits first.

But for general interests, there is no need to go to this extent.

Anna suggested this just to give it a try.

Given Pfizer's current situation, it is basically impossible for it to give up on such a high-quality anti-cancer project.

Therefore, Novartis has no chance of picking up a bargain, and she does not hold out much hope. She is mainly keeping an eye on it and does not expect that it will be her turn to acquire it.

But it doesn't matter what.

Pfizer's sudden attention to this project has also attracted attention from all parties.

Everyone is researching this anti-cancer project. How big is the future market and is it really worth investing in?

After all, many people know that Pfizer wants to make a comeback with this project, so naturally they need to understand the latest situation.

……

And about Pfizer's plan to acquire an anti-cancer drug project.

Chen Xuan is also concerned about this and is now considering this issue.

After all, he is shorting Pfizer, and if there is good news, it will definitely be detrimental to his shorting.

“Whatever happens with this project is fine.”

"But if Pfizer really acquires it, it will definitely be portrayed as good news."